Tedi Qendro1,2, María Laura de la Torre1,2, Pantelis Panopalis1,2, Elizabeth Hazel1,2, Brian J Ward1,2, Inés Colmegna1,2, Marie Hudson3,4. 1. From the Department of Medicine, McGill University, Montreal; Division of Rheumatology, McGill University Health Center, Montreal; Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Center, Montreal; Division of Rheumatology and Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada; Internal Medicine, Rheumatology and Immunology, Centro de Educacion Medica e Investigaciones Clinicas Norberto Quirno, Buenos Aires, Argentina. 2. T. Qendro, MSc, Department of Medicine, McGill University; M.L. de la Torre, MD, Internal medicine, Rheumatology and Immunology, Centro de Educacion Medica e Investigaciones Clinicas Norberto Quirno; P. Panopalis, MD, Division of Rheumatology, McGill University Health Center; E. Hazel, MD, Division of Rheumatology, McGill University Health Center; B.J. Ward, MD, DTM&H, Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Center; I. Colmegna, MD, Division of Rheumatology, McGill University Health Center; M. Hudson, MD, MPH, FRCPC, Division of Rheumatology and Lady Davis Institute for Medical Research, Jewish General Hospital. 3. From the Department of Medicine, McGill University, Montreal; Division of Rheumatology, McGill University Health Center, Montreal; Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Center, Montreal; Division of Rheumatology and Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada; Internal Medicine, Rheumatology and Immunology, Centro de Educacion Medica e Investigaciones Clinicas Norberto Quirno, Buenos Aires, Argentina. marie.hudson@mcgill.ca. 4. T. Qendro, MSc, Department of Medicine, McGill University; M.L. de la Torre, MD, Internal medicine, Rheumatology and Immunology, Centro de Educacion Medica e Investigaciones Clinicas Norberto Quirno; P. Panopalis, MD, Division of Rheumatology, McGill University Health Center; E. Hazel, MD, Division of Rheumatology, McGill University Health Center; B.J. Ward, MD, DTM&H, Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Center; I. Colmegna, MD, Division of Rheumatology, McGill University Health Center; M. Hudson, MD, MPH, FRCPC, Division of Rheumatology and Lady Davis Institute for Medical Research, Jewish General Hospital. marie.hudson@mcgill.ca.
Abstract
OBJECTIVE: To assess vaccination coverage and predictors of vaccination among a Canadian population of rheumatology patients in routine clinical care. METHODS: In this cross-sectional study, consecutive adult patients presenting to a tertiary rheumatology clinic at the McGill University Health Center between May and September 2015 were asked to fill a survey on vaccination. Patients self-identified as having rheumatoid arthritis (RA), systemic autoimmune rheumatic diseases (SARD), spondyloarthropathies (SpA), or other diseases (OD). Multivariate logistical regression analyses were performed to evaluate patient and physician factors associated with various vaccinations [for influenza, pneumococcus, and hepatitis B virus (HBV)]. Published Quebec general population influenza and pneumococcal vaccination rates in those aged ≥ 65 years were used as comparative baseline rates. RESULTS: Three hundred fifty-two patients were included in the analysis (RA: 136, SARD: 113, SpA: 47, OD: 56). Vaccination rates were reported as follows: (1) influenza: RA 48.5%, SARD 42.0%, SpA 31.9%, OD 88.9%, Quebec general population 58.5%; (2) pneumococcal: RA 42.0%, SARD 37.8%, SpA 29.7%, OD 33.3%, Quebec general population 53.2%; (3) HBV: RA 33.6%, SARD 55.6%, SpA 73.5%, OD 36.8%; and (4) herpes zoster: RA 5.6%, SARD 28.6%, SpA 25.0%, OD 16.7%. Physician recommendation was the strongest independent predictor of vaccination across all vaccine types (influenza: OR 8.56, 95% CI 2.80-26.2, p < 0.001; pneumococcal: OR 314, 95% CI 73.0-1353, p < 0.001; HBV: OR 12.8, 95% CI 5.27-31.1, p < 0.001). Disease group, disease duration, comorbidities, treatment type, and being followed by a primary care physician were not significantly associated with vaccination. CONCLUSION: There is suboptimal immunization coverage among ambulatory rheumatology patients. An important role for patient and physician education is highlighted in our study, especially because physician recommendation of vaccination was strongly predictive of vaccine uptake.
OBJECTIVE: To assess vaccination coverage and predictors of vaccination among a Canadian population of rheumatologypatients in routine clinical care. METHODS: In this cross-sectional study, consecutive adult patients presenting to a tertiary rheumatology clinic at the McGill University Health Center between May and September 2015 were asked to fill a survey on vaccination. Patients self-identified as having rheumatoid arthritis (RA), systemic autoimmune rheumatic diseases (SARD), spondyloarthropathies (SpA), or other diseases (OD). Multivariate logistical regression analyses were performed to evaluate patient and physician factors associated with various vaccinations [for influenza, pneumococcus, and hepatitis B virus (HBV)]. Published Quebec general population influenza and pneumococcal vaccination rates in those aged ≥ 65 years were used as comparative baseline rates. RESULTS: Three hundred fifty-two patients were included in the analysis (RA: 136, SARD: 113, SpA: 47, OD: 56). Vaccination rates were reported as follows: (1) influenza: RA 48.5%, SARD 42.0%, SpA 31.9%, OD 88.9%, Quebec general population 58.5%; (2) pneumococcal: RA 42.0%, SARD 37.8%, SpA 29.7%, OD 33.3%, Quebec general population 53.2%; (3) HBV: RA 33.6%, SARD 55.6%, SpA 73.5%, OD 36.8%; and (4) herpes zoster: RA 5.6%, SARD 28.6%, SpA 25.0%, OD 16.7%. Physician recommendation was the strongest independent predictor of vaccination across all vaccine types (influenza: OR 8.56, 95% CI 2.80-26.2, p < 0.001; pneumococcal: OR 314, 95% CI 73.0-1353, p < 0.001; HBV: OR 12.8, 95% CI 5.27-31.1, p < 0.001). Disease group, disease duration, comorbidities, treatment type, and being followed by a primary care physician were not significantly associated with vaccination. CONCLUSION: There is suboptimal immunization coverage among ambulatory rheumatologypatients. An important role for patient and physician education is highlighted in our study, especially because physician recommendation of vaccination was strongly predictive of vaccine uptake.
Entities:
Keywords:
CANADA; PREVENTIVE HEALTH SERVICES; QUEBEC; RHEUMATIC DISEASES; VACCINATION COVERAGE
Authors: Valeria Valerio; Maria Celia Bazan; Mianbo Wang; Bruce D Mazer; Christian A Pineau; Elizabeth M Hazel; Sasha Bernatsky; Brian J Ward; Ines Colmegna Journal: Clin Rheumatol Date: 2020-10-08 Impact factor: 2.980
Authors: Dominik Schröder; Stephanie Heinemann; Alexandra Jablonka; Frank Müller; Gloria Heesen; Frank Klawonn; Marie Mikuteit; Jacqueline Niewolik; Sandra Steffens; Georg Behrens Journal: Eur J Med Res Date: 2022-06-22 Impact factor: 4.981
Authors: Viviane Ta; Orit Schieir; Marie-France Valois; Ines Colmegna; Carol Hitchon; Louis Bessette; Glen Hazlewood; Carter Thorne; Janet Pope; Gilles Boire; Diane Tin; Edward C Keystone; Vivian P Bykerk; Susan J Bartlett Journal: ACR Open Rheumatol Date: 2022-03-29
Authors: Ruth Ann Marrie; Randy Walld; James M Bolton; Jitender Sareen; Scott B Patten; Alexander Singer; Lisa M Lix; Carol A Hitchon; James J Marriott; Renée El-Gabalawy; Alan Katz; John D Fisk; Charles N Bernstein Journal: CMAJ Open Date: 2021-05-14
Authors: Sara Labbé; Inés Colmegna; Valeria Valerio; Vincent Gosselin Boucher; Sandra Peláez; Anda I Dragomir; Catherine Laurin; Elizabeth M Hazel; Simon L Bacon; Kim L Lavoie Journal: Vaccines (Basel) Date: 2022-01-19
Authors: Valeria Valerio; Marie Hudson; Mianbo Wang; Sasha Bernatsky; Elizabeth M Hazel; Brian Ward; Inés Colmegna Journal: ACR Open Rheumatol Date: 2022-01-20